ArticleJournal of cardiothoracic surgery2025
Comparative analysis of antiangiogenic and immunotherapeutic regimens in the treatment of metastatic pulmonary lymphoepithelioma-like carcinoma.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivePulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare histological subtype of non-small cell lung cancer for which no standard treatment protocol exists in the metastatic setting. This study aims to evaluate the efficacy and safety of antiangiogenic agents and immune checkpoint inhibitors (ICIs), individually and in combination with cytotoxic chemotherapy, in patients diagnosed with metastatic PLELC. The findings aim to inform therapeutic strategies for this uncommon malignancy.
methodA retrospective analysis of electronic medical records was performed to identify patients diagnosed with metastatic PLELC. Based on the treatment regimens received, participants were stratified into three groups: antiangiogenic agents plus ICIs (AI group), antiangiogenic agents plus ICIs and cytotoxic chemotherapy (AIC group), and antiangiogenic agents plus cytotoxic chemotherapy without ICIs (AC group).
resultsNineteen patients were included in the analysis. The overall objective response rate (ORR) was 78.9% (15/19), the disease control rate (DCR) was 94.8% (18/19), and the median progression-free survival (mPFS) was 12.9 months. In the AIC group, the ORR was 72.7% (8/11), the DCR was 90.9% (10/11), and the mPFS was 16.0 months. In the AI group, the ORR was 83.3% (5/6), the DCR was 100% (6/6), and the mPFS was 12.35 months. In the AC group, both the ORR and DCR were 100% (2/2), with an mPFS of 6.45 months. Patients in the AIC group exhibited substantial tumor regression. Furthermore, those with programmed death-ligand 1 (PD-L1) expression ≥ 50% experienced significantly prolonged mPFS compared to patients with PD-L1 expression < 50%. Following disease progression, clinical conditions remained stable under subsequent antiangiogenic therapy.
conclusionThe combination of antiangiogenic agents, ICIs, and cytotoxic chemotherapy demonstrated promising efficacy and an acceptable safety profile in the treatment of metastatic PLELC. These findings support further exploration of multi-modality regimens in this rare lung cancer subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.